Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.

ABSTRACT:

Importance

Newer antiobesity medications lead to greater weight loss and lower cardiometabolic risks. However, the high costs of these medications have raised policy questions about their value and coverage decisions.

Objective

To compare the cost-effectiveness of 4 antiobesity medications with lifestyle modification vs lifestyle modification alone in the US.

Design, setting, and participants

A lifetime cost-effectiveness analysis was conducted in 2024 using the validated Diabetes, Obesity, Cardiovascular Disease Microsimulation model for US adults. Data were included from the 2017-2020 National Health and Nutrition Examination Survey of 4823 individuals (representing 126 million eligible US adults) aged 20 to 79 years who would meet clinical trial inclusion criteria

SUBMITTER: Hwang JH 

PROVIDER: S-EPMC11909610 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature